Related Experiment Video

Updated: Jun 22, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells

Zu-Quan Zou1, Xiao-Hong Zhang, Feng Wang

  • 1Department of Food Science and Nutrition, Zhejiang University, Hangzhou, PR China.

International Journal of Molecular Medicine
|June 11, 2009
PubMed

Insights

PI-103 effectively treats gefitinib-resistant non-small cell lung cancer (NSCLC) by inhibiting PI3Kalpha and mTOR. This multitargeted therapy induces cell cycle arrest and shows promise for difficult-to-treat NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Gefitinib resistance is a significant challenge in non-small cell lung cancer (NSCLC) treatment.
  • Targeting the PI3K/Akt/mTOR pathway is a promising strategy for cancer therapy.
  • PI-103 is a novel synthetic compound inhibiting both PI3Kalpha and mTOR.

Purpose of the Study:

  • To evaluate the antitumor activity of PI-103 in gefitinib-resistant NSCLC cell lines.
  • To investigate the molecular mechanisms underlying PI-103's efficacy.
  • To determine the role of PIK3CA mutations in PI-103 sensitivity.

Main Methods:

  • Treatment of NSCLC cell lines (A549, H460) with PI-103.
  • Assessment of cell viability and proliferation.
  • Western blotting to analyze key proteins in the PI3K/Akt/mTOR pathway and cell cycle regulators.
  • Analysis of cell cycle progression using flow cytometry.

Main Results:

  • PI-103 demonstrated significant antitumor activity in gefitinib-resistant A549 and H460 NSCLC cells.
  • PI-103 induced G0-G1 cell cycle arrest by down-regulating cyclins D1/E1 and up-regulating p21/p27.
  • Upregulation of p53 was observed, correlating with p21 induction.
  • Cells with PIK3CA mutations (H460) were more sensitive to PI-103 than wild-type cells (A549).

Conclusions:

  • PI-103 exhibits potent antitumor effects in gefitinib-resistant NSCLC.
  • The combination of PI3Kalpha and mTOR inhibition is a viable therapeutic strategy.
  • PI-103 holds promise as a treatment for advanced or resistant NSCLC.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...